In this report, the EMEA Glucagon market is valued at USD XX million in 2017 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2017 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Glucagon for these regions, from 2013 to 2025 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Glucagon market competition by top manufacturers/players, with Glucagon sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
Novo Nordisk
Eli Lilly
Fresenius Kabi
Torrent Labs
Taj Pharmaceuticals
Xeris Pharmaceuticals
...

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
Inject Glucagon
Nasal Glucagon

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
Emergency Kits
General Use
Diagnostic & Motility
Cardiogenic Shock
Others